What Is Retatrutide? The GLP-3 Triple-Hormone Breakthrough Explained

Posted on July 3, 2026 by Dr. Donald Vollmer, MD

What Is Retatrutide? The GLP-3 Triple-Hormone Breakthrough Explained

July 3, 2026

Every few years a new weight-loss medication comes along that changes the conversation. Right now, that name is retatrutide. It has produced some of the largest weight-loss results ever recorded in a medication trial, and people who have struggled for years are paying close attention. If you have been wondering what all the excitement is about, you are in the right place.

So what is retatrutide, and why does it have the weight-loss world so energized? In plain terms, it is a next-generation injectable that works with three of your body’s hormones at once to reduce appetite and help you burn energy. It is still finishing its final research stage, but the early results are remarkable. Here is a clear, no-hype breakdown, plus what you can do today at Franklin, TN and Nolensville, TN.

What Is Retatrutide?

Retatrutide is a once-weekly injectable medication developed by Eli Lilly, currently known in research as LY3437943. It belongs to the same broad family as today’s popular weight-loss shots, but it goes a step further by acting on three hormone pathways instead of one or two. That is why it is often called a “triple agonist” or “triple-G.” You may also see it called a “GLP-3.” That nickname is not an official drug class, but it caught on because retatrutide reaches one step beyond the GLP-1 medications most people already know.

What has people excited is the scale of the results. In a 2023 phase 2 trial published in the New England Journal of Medicine, adults with obesity on the highest dose lost an average of 24.2 percent of their body weight over 48 weeks. That is among the highest averages ever reported for a weight-loss medication, which is why retatrutide is considered such a promising step forward.

How Does Retatrutide Work in the Body?

Retatrutide works by activating three hormone receptors that influence hunger, blood sugar, and energy use: GIP, GLP-1, and glucagon. The first two help reduce appetite and slow digestion so you feel full longer, the same mechanisms behind today’s leading medications. The third, glucagon, adds something extra by helping the body use more energy. Those three pathways working together are what people are describing when they use the shorthand “GLP-3.”

That third pathway is the key difference. By combining appetite reduction with increased energy use, retatrutide addresses weight from more than one angle at the same time. Research also points to benefits beyond the scale: a 2024 study in Nature Medicine found retatrutide dramatically reduced fat stored in the liver, an important marker of metabolic health.

How Much Weight Did People Lose in Retatrutide Studies?

Across its trials, retatrutide has consistently produced strong weight-loss results. The obesity study showed an average loss of about 24 percent at the highest dose. A separate phase 2 trial in adults with type 2 diabetes, published in The Lancet, showed meaningful weight loss along with improved blood-sugar control.

These results are why retatrutide has generated so much attention, but it is worth keeping perspective. Every person responds differently, results depend on dose and consistency, and the medication is still being studied in its largest trials. The numbers are genuinely exciting, and they are still being confirmed in the research that will support approval.

Is Retatrutide the Same Thing as a GLP-3?

Yes. “GLP-3” is an informal nickname the internet gave retatrutide, not a real receptor or an official drug class. It stuck because semaglutide targets one pathway and tirzepatide targets two, so a medication targeting three sounded like the next number in the sequence. Retatrutide is still working through a large phase 3 research program, and you can see the flagship study, enrolling thousands of participants, on the government registry for the TRIUMPH-1 phase 3 trial.

If a GLP-3 is on your radar, the useful question is not a date on a calendar, it is which supervised option fits your body and your goals right now. That is what our providers do in a free consultation, and it is what our post on retatrutide availability in Tennessee walks through.

What Can You Do About Weight Loss Today at Body Works?

You do not have to wait to start making progress. Body Works offers physician-supervised medical weight-loss programs with semaglutide and tirzepatide, two proven medications available right now. In the SURMOUNT-1 trial, tirzepatide produced an average weight loss of about 22.5 percent, results very close to early retatrutide data.

With offices in Franklin and Nolensville, Body Works gives you a personalized plan, real medical oversight, and a team that tracks the science so you always know your best options. Want to see which approach fits you? Schedule a Free Consultation. You can also compare your choices in our guide to retatrutide, tirzepatide, and semaglutide or learn how GLP-1 medications work.

Frequently Asked Questions

Does a GLP-3 work for weight loss?

In its phase 2 trial, retatrutide, the medication people call a GLP-3, produced an average weight loss of about 24 percent of body weight over 48 weeks, among the highest figures reported for this class. It is still completing the research needed for approval. Our providers can walk you through which supervised option is the right fit for you today.

Is retatrutide a GLP-1 or a GLP-3?

Neither label is official. “GLP-1” describes medications acting on a single pathway, and “GLP-3” is an internet nickname for retatrutide because it acts on three: GIP, GLP-1, and glucagon. That broader action is why early studies showed such strong results.

What do these weight-loss options cost?

Cost depends on the medication and the plan you and your provider build together. The most useful step is a free consultation, where we discuss the options you can start and what to expect. Body Works also offers flexible payment plans.

Is retatrutide safe?

Retatrutide is being studied in large, carefully designed trials specifically to confirm its safety and effectiveness. Any weight-loss medication is safest when prescribed and monitored by licensed providers, which is how every Body Works program is run.

Where can I learn about weight-loss options near me?

Body Works offers physician-supervised weight-loss care at two Middle Tennessee locations, Franklin and Nolensville. Both provide supervised programs today, and both follow the research closely so your plan always reflects your best available option.

Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN

Browse Our Blog

Loose Skin After Weight Loss: Causes, Prevention, and Treatment

August 10, 2026

Loose skin after major or GLP-1 weight loss is common, and it worries a lot of people. Here is what causes it, which factors decide

Body Changes After GLP-1 Weight Loss: The Complete Guide

August 6, 2026

Rapid weight loss changes more than the number on the scale. Here is what happens to your face, skin, muscle, and body shape on GLP-1

GLP-1s and Hormone Therapy for Women: What New Research Shows

August 2, 2026

A new retrospective study found postmenopausal women on tirzepatide lost noticeably more weight when they also used menopause hormone therapy. Here is what the research

GLP-1 Pill vs Injection: What to Know About Oral GLP-1s

July 29, 2026

Oral GLP-1 medications promise the same appetite control as injections without the needle, but strict fasting windows and absorption limits change the picture. Here is

Skin Tightening After Weight Loss: Non-Surgical Options Compared

July 25, 2026

Loose skin after weight loss has more non-surgical options than ever. Here is how the main skin tightening approaches compare and how to choose one.

Is Ozempic Face Reversible? What Fillers and Collagen Can and Cannot Do

July 22, 2026

Rapid weight loss can leave the face looking hollow. Here is an honest look at what dermal fillers, biostimulators, and collagen support can and cannot

Retatrutide vs. Tirzepatide vs. Semaglutide: How the Triple Agonist Compares

Posted on June 29, 2026August 23, 2026 by Dr. Donald Vollmer, MD

Retatrutide vs. Tirzepatide vs. Semaglutide: How the Triple Agonist Compares

June 29, 2026

The core difference between semaglutide, tirzepatide, and retatrutide is how many hormone pathways each one activates: semaglutide works on one, tirzepatide on two, and retatrutide, the newcomer some call a “GLP-3,” on three. That is also the order of strength in early trial results.

The practical upshot of the retatrutide vs tirzepatide question: retatrutide leads the early trial numbers, but semaglutide and tirzepatide have the longest real-world track record and are the ones you can start today. This guide breaks down how the three compare on weight loss, how they work, and how to pick the right path at Franklin, TN and Nolensville, TN.

Retatrutide vs. Tirzepatide vs. Semaglutide: What Is the Difference?

The core difference is how many hormone pathways each medication activates. Semaglutide works on one pathway (GLP-1). Tirzepatide works on two (GIP and GLP-1). Retatrutide works on three, adding glucagon, which is why it is nicknamed the triple agonist or “triple-G.” It is also the medication people mean when they say “GLP-3,” a nickname rather than an official drug class. Each added pathway gives the body another way to reduce appetite and, in retatrutide’s case, to increase energy use.

Think of it as a ladder. In a 2023 phase 2 trial in the New England Journal of Medicine, retatrutide’s triple action produced the largest average weight loss reported for this class of medication. More pathways is not automatically better for every person, but it helps explain why retatrutide has generated so much excitement.

Which One Leads to the Most Weight Loss?

In their respective trials, retatrutide produced the highest average weight loss, followed by tirzepatide, then semaglutide. Retatrutide reached about 24 percent average body-weight loss at 48 weeks in its phase 2 study. Tirzepatide reached about 22.5 percent in the SURMOUNT-1 trial, and semaglutide reached about 15 percent in the STEP 1 trial.

One important caveat: these numbers come from separate studies with different participants and lengths, so they are not a true head-to-head comparison. What they do show is that all three are highly effective, and that tirzepatide, available today, delivers results very close to what early retatrutide studies report.

Medication	Hormone pathways	Avg. weight loss in trials	Available today?
Semaglutide	1 (GLP-1)	About 15%	Yes, at Body Works
Tirzepatide	2 (GIP, GLP-1)	About 22.5%	Yes, at Body Works
Retatrutide	3 (GIP, GLP-1, glucagon)	About 24%	Ask our providers

Should You Wait for Retatrutide or Start With Tirzepatide Now?

For most people, the better move is to start now rather than wait. Retatrutide is still working through its phase 3 TRIUMPH research program and where things stand today is worth talking through with a provider rather than guessing from a headline. Waiting means postponing the health benefits you could be gaining now.

Because tirzepatide already delivers results close to early retatrutide data, many people who are curious about retatrutide start with a supervised tirzepatide or semaglutide plan and reassess with their provider as the field evolves. An established relationship makes any future transition smooth. You can read more about how these medications work to decide what fits your goals.

How Do the Side Effects Compare?

All three medications share a similar side-effect profile because they act on related hormone pathways. The most common effects are digestive, such as nausea, reduced appetite, and occasional stomach upset, especially when first increasing the dose. In the phase 2 retatrutide study in The Lancet, side effects were mostly mild to moderate and tended to ease over time, a pattern also seen with semaglutide and tirzepatide.

This is exactly why medical supervision matters. A provider adjusts your dose gradually, helps you manage any early side effects, and monitors your progress so the plan stays comfortable and effective. Side effects are far more manageable with a personalized, physician-guided approach than with a one-size-fits-all schedule.

How to Choose the Right Weight-Loss Medication in Tennessee

The best medication is the one that fits your body, your health history, and your goals, and that decision is easier with expert guidance. Body Works offers physician-supervised medical weight-loss programs with both semaglutide and tirzepatide, and a team that follows the science on retatrutide closely so you always know your best options.

With locations in Franklin and Nolensville, you get local, in-person care and a plan built specifically for you. Curious which option is right for you today, and how retatrutide might fit later? Schedule a Free Consultation to map it out. You may also like our guide to keeping the weight off for good.

Frequently Asked Questions

Is retatrutide better than tirzepatide?

In early studies, retatrutide produced slightly higher average weight loss than tirzepatide, but the two have never been compared directly in the same trial. Which one is right for you depends on your history and your goals, so the most useful step is a free consultation where our providers can walk you through it.

Is retatrutide the same as a GLP-3?

Yes. “GLP-3” is a nickname the internet gave retatrutide, not an official drug class or a real receptor. Retatrutide acts on three pathways: GIP, GLP-1, and glucagon. If you are trying to decide between the options in this category, book a free consultation and we will help you sort out what fits.

How much do these weight-loss medications cost?

Cost depends on the medication and your personalized plan. The most useful next step is a free consultation, where we review the options and payment plans together. Body Works focuses on finding a plan that fits your budget and your goals.

Which medication has the fewest side effects?

All three share a similar, mostly digestive side-effect profile that often eases over time. There is no single answer for everyone, which is why a gradual, supervised dosing plan matters. Your provider tailors the approach to keep side effects minimal while protecting your results.

Where can I get semaglutide or tirzepatide near me?

Body Works provides physician-supervised weight-loss programs at two Middle Tennessee locations, Franklin and Nolensville. Both offer personalized dosing and ongoing monitoring, and both stay current on the newest research so your plan reflects your best option.

Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN

Browse Our Blog

Loose Skin After Weight Loss: Causes, Prevention, and Treatment

August 10, 2026

Loose skin after major or GLP-1 weight loss is common, and it worries a lot of people. Here is what causes it, which factors decide

Body Changes After GLP-1 Weight Loss: The Complete Guide

August 6, 2026

Rapid weight loss changes more than the number on the scale. Here is what happens to your face, skin, muscle, and body shape on GLP-1

GLP-1s and Hormone Therapy for Women: What New Research Shows

August 2, 2026

A new retrospective study found postmenopausal women on tirzepatide lost noticeably more weight when they also used menopause hormone therapy. Here is what the research

GLP-1 Pill vs Injection: What to Know About Oral GLP-1s

July 29, 2026

Oral GLP-1 medications promise the same appetite control as injections without the needle, but strict fasting windows and absorption limits change the picture. Here is

Skin Tightening After Weight Loss: Non-Surgical Options Compared

July 25, 2026

Loose skin after weight loss has more non-surgical options than ever. Here is how the main skin tightening approaches compare and how to choose one.

Is Ozempic Face Reversible? What Fillers and Collagen Can and Cannot Do

July 22, 2026

Rapid weight loss can leave the face looking hollow. Here is an honest look at what dermal fillers, biostimulators, and collagen support can and cannot

Retatrutide (GLP-3) Availability in Tennessee: What to Know

Posted on June 25, 2026August 23, 2026 by Dr. Donald Vollmer, MD

Retatrutide (GLP-3) Availability in Tennessee: What to Know

June 25, 2026

Retatrutide is not yet available: the medication a lot of people now search for as a “GLP-3” is still working through late-stage clinical trials and has not been approved for prescription use. It is also the most talked-about weight-loss medication in years, because in early studies people taking it lost more weight than with any injectable in wide use today. So the real question is what you should be doing about your own goals right now.

Here is the encouraging part. You do not have to sit on the sidelines while this category evolves. The smartest patients are getting a head start now with a proven, physician-guided program, so they are already lean, already established with a trusted local team, and already ahead of the crowd. This guide walks through what retatrutide is, where retatrutide availability stands right now, and how to build momentum today at Franklin, TN and Nolensville, TN.

What Is Retatrutide, and Why Is Everyone Talking About It?

Retatrutide is a once-weekly injectable being developed as the next generation of weight-loss medication. What makes it special is that it works on three different hormone pathways at once, GIP, GLP-1, and glucagon, which is why it is nicknamed the “triple-G” or triple agonist. You may also see it called a “GLP-3” online. That is not an official drug class, but the nickname stuck because retatrutide reaches a step beyond the GLP-1 medications most people already know. Today’s leading medications act on one or two of these pathways. Retatrutide adds a third lever that also helps the body burn energy, not just reduce appetite.

The excitement is grounded in real results. In a 2023 phase 2 trial published in the New England Journal of Medicine, adults with obesity taking the highest dose of retatrutide lost an average of 24.2 percent of their body weight over 48 weeks, a level of weight reduction that had rarely been seen with medication alone. A separate phase 2 study in adults with type 2 diabetes, published in The Lancet, showed strong weight and blood-sugar improvements as well.

Retatrutide Availability: Where the Approval Process Stands Today

Retatrutide, the medication most people are searching for when they type “GLP-3,” is moving through a large phase 3 research program designed to confirm how well it works and how safely it performs over the long term. You can see the flagship study, which is enrolling thousands of participants, on the government registry for the TRIUMPH-1 phase 3 retatrutide trial.

This category is moving quickly, and what is appropriate for any one patient depends on their history, their goals, and their full medical picture. That is a conversation, not something a web page can answer. The most useful step is to sit down with our providers, review where your health stands, and let us walk you through which supervised option makes the most sense for you right now.

How Does Retatrutide Compare to the Options You Can Get Today?

Retatrutide is the future, but the medications available right now are genuinely excellent and have helped millions of people transform their health. Semaglutide and tirzepatide, both offered at Body Works, deliver powerful, well-documented results, and you can start either one today under medical supervision.

In the SURMOUNT-1 trial in the New England Journal of Medicine, adults on the highest dose of tirzepatide lost an average of 22.5 percent of their body weight over 72 weeks. Earlier, the STEP 1 trial of semaglutide showed an average loss of nearly 15 percent. These are proven, available tools you can put to work immediately.

Medication	How it works	Available today?
Semaglutide	Single pathway (GLP-1)	Yes, at Body Works
Tirzepatide	Dual pathway (GIP and GLP-1)	Yes, at Body Works
Retatrutide	Triple pathway (GIP, GLP-1, and glucagon)	Ask our providers

For a deeper side by side, read our full retatrutide vs. tirzepatide vs. semaglutide comparison.

What Is the Smartest Move While You Wait for Retatrutide?

The smartest move is to start now rather than pause your goals. Every month you spend closer to your target weight is a month of better energy, better health markers, and real momentum, and the habits and medical relationship you build today carry straight over to whatever comes next. As newer options reach patients, you will be in an even stronger position to benefit from them.

Starting with a supervised semaglutide or tirzepatide program also means you are working with a provider who understands how these medications work at the hormone level and how to keep your results safe and steady. Every medication we use is dispensed through licensed providers under the framework that governs which medications a pharmacy may prepare, described in the FDA’s compounding standards for pharmacies. Being an established patient means your provider can move quickly as your best option changes.

Why Start Your Weight-Loss Program With Body Works?

Body Works runs physician-supervised medical weight-loss programs built around your body, your history, and your goals, not a one-size-fits-all script. That means real medical oversight, dosing tailored to you, and a team that stays current on the science so you always know what your best options are, today and as the field evolves.

It also means local, in-person care. With offices in Franklin and Nolensville, you get a provider you can actually sit down with, plus support for building the habits that make results last. If retatrutide is on your radar, the best first step is a conversation. Schedule a Free Consultation and start your momentum now, with a team ready to guide you every step of the way. You can also explore our tips for succeeding with medical weight-loss injections and keeping the weight off for good.

Frequently Asked Questions

Is retatrutide a GLP-1 or a GLP-3?

“GLP-3” is an informal nickname rather than an official drug class. It refers to retatrutide, which acts on three hormone pathways: GIP, GLP-1, and glucagon. Standard GLP-1 medications act on just one. If you are weighing your options, schedule a free consultation and our providers will help you determine which supervised program fits you best.

How is retatrutide different from semaglutide and tirzepatide?

Semaglutide works on one hormone pathway and tirzepatide works on two. Retatrutide works on three, adding a glucagon pathway that also helps the body burn energy. That third pathway is why it is called a triple agonist, or a “GLP-3” in casual conversation.

What do weight-loss medications cost?

Cost depends on the medication and the plan your provider builds with you. The most useful step is a free consultation, where we review your options together and answer your questions. Body Works also offers flexible payment plans.

Is retatrutide safe?

Retatrutide is being studied in large, carefully designed trials precisely to confirm its long-term safety and effectiveness. Any weight-loss medication is safest when it is prescribed and monitored by licensed medical providers, which is how every program at Body Works is run.

Where can I start a weight-loss program near me?

Body Works offers physician-supervised medical weight-loss care at two convenient Middle Tennessee locations, Franklin and Nolensville. Both provide supervised programs today, and both stay current on the newest research so your plan reflects your best available option.

Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN

Browse Our Blog

Loose Skin After Weight Loss: Causes, Prevention, and Treatment

August 10, 2026

Loose skin after major or GLP-1 weight loss is common, and it worries a lot of people. Here is what causes it, which factors decide

Body Changes After GLP-1 Weight Loss: The Complete Guide

August 6, 2026

Rapid weight loss changes more than the number on the scale. Here is what happens to your face, skin, muscle, and body shape on GLP-1

GLP-1s and Hormone Therapy for Women: What New Research Shows

August 2, 2026

A new retrospective study found postmenopausal women on tirzepatide lost noticeably more weight when they also used menopause hormone therapy. Here is what the research

GLP-1 Pill vs Injection: What to Know About Oral GLP-1s

July 29, 2026

Oral GLP-1 medications promise the same appetite control as injections without the needle, but strict fasting windows and absorption limits change the picture. Here is

Skin Tightening After Weight Loss: Non-Surgical Options Compared

July 25, 2026

Loose skin after weight loss has more non-surgical options than ever. Here is how the main skin tightening approaches compare and how to choose one.

Is Ozempic Face Reversible? What Fillers and Collagen Can and Cannot Do

July 22, 2026

Rapid weight loss can leave the face looking hollow. Here is an honest look at what dermal fillers, biostimulators, and collagen support can and cannot

Tirzepatide Deep Dive: Dosing, Results, and What Patients Should Expect

Posted on April 26, 2026May 11, 2026 by Dr. Donald Vollmer, MD

Tirzepatide Deep Dive: Dosing, Results, and What Patients Should Expect

April 26, 2026

Tirzepatide is the newer of the two leading weight loss medications, and over the past two years it has been quietly displacing Body Works semaglutide therapy as the first-line choice for many physicians. The reason is not marketing. It is mechanism. Tirzepatide activates two metabolic receptor systems simultaneously, where semaglutide activates one, and that single design difference produces measurably larger weight loss in head-to-head clinical comparisons.

For patients researching tirzepatide as a primary option, or considering switching from semaglutide, the questions that matter are not the same as the general GLP-1 questions. Tirzepatide has its own dosing schedule, its own side-effect profile, its own response pattern, and its own clinical fit. Treating it as interchangeable with semaglutide misses the parts that make it the right choice for some patients and the wrong choice for others.

This guide walks through how tirzepatide works, what the SURMOUNT trial data actually shows, the dosing schedule from week one through maintenance, the side-effect picture compared to semaglutide, and what to expect if you start treatment at a physician-supervised program. If you are still deciding between the two medications, our comparison post covers that question more directly. This post goes deeper on tirzepatide as a standalone clinical decision.

How Tirzepatide Works

Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). Semaglutide activates only the GLP-1 receptor. GIP is a second incretin hormone that, like GLP-1, is released from the gut after eating and influences insulin secretion, satiety, and energy balance.

The dual mechanism is not just additive. The two receptors interact in ways that appear to amplify each other’s effects on appetite suppression and metabolic regulation. Patients on tirzepatide often report stronger and more sustained satiety than they experienced on semaglutide, particularly at the higher dose levels. The slowed gastric emptying that drives GLP-1 nausea is also present with tirzepatide, but the GIP component appears to attenuate it somewhat, contributing to a slightly better tolerability profile in some patients.

The same dual mechanism affects metabolic markers beyond weight. Tirzepatide produces larger improvements in HbA1c, fasting glucose, and lipid markers than semaglutide does, on average. For patients whose weight gain is intertwined with prediabetes, type 2 diabetes, or metabolic syndrome, the dual-agonist effect on glucose handling is clinically meaningful in addition to the weight loss benefit.

The SURMOUNT Trial Results: What 22.5% Weight Loss Means in Practice

The pivotal trial for tirzepatide in chronic weight management was SURMOUNT-1. Adults with obesity received tirzepatide at 5 mg, 10 mg, or 15 mg weekly, or placebo, for 72 weeks. Mean weight loss at the highest dose was 22.5%, compared to 2.4% on placebo (Jastreboff et al., New England Journal of Medicine, 2022). The 10 mg dose produced 21.4% weight loss, and the 5 mg dose produced 16.0%.

For a 220-pound patient, 22.5% works out to approximately 50 pounds. For comparison, semaglutide 2.4 mg in the STEP 1 trial produced 14.9% weight loss over 68 weeks, which is roughly 33 pounds for the same starting weight. The gap is not subtle. Tirzepatide produces more weight loss on average.

The trial also showed that the share of patients hitting larger weight loss thresholds was substantially higher on tirzepatide. Roughly 40% of patients on tirzepatide 15 mg lost at least 25% of their body weight. About 15% lost at least 30%. Those numbers are well above what semaglutide produces and put tirzepatide in a weight loss range that previously was achievable only with bariatric surgery for many patients.

Subsequent trials extended the picture. SURMOUNT-2 evaluated tirzepatide in adults with type 2 diabetes and obesity, finding 12.8% weight loss at 15 mg over 72 weeks, smaller than the non-diabetic population but still substantially larger than semaglutide produces in the same group (Garvey et al., The Lancet, 2023). SURMOUNT-4 confirmed that continued treatment preserved weight loss and that discontinuation produced regain, in line with the pattern seen with semaglutide.

The dose-by-dose breakdown from SURMOUNT-1 makes the response curve concrete:

Tirzepatide dose	Mean weight change at 72 weeks	Patients losing 20% or more
5 mg	-15.0%	30.0%
10 mg	-19.5%	50.1%
15 mg	-20.9%	56.7%

Most of the weight-loss benefit is captured by the 10 mg dose. The step from 10 mg to 15 mg adds an additional reduction, but the curve flattens, and the side-effect cost rises. For many patients, 10 mg is the right long-term maintenance dose; the decision to push higher is a clinical judgment that weighs marginal benefit against tolerance.

Tirzepatide Dosing Schedule Week by Week

Tirzepatide is administered as a once-weekly subcutaneous injection. The titration schedule starts at 2.5 mg and steps up at four-week intervals, with a target maintenance dose typically between 5 mg and 15 mg depending on the patient’s response and tolerance.

The standard schedule for chronic weight management:

Weeks 1 to 4: 2.5 mg weekly. This is a titration step, not a therapeutic dose. The job is acclimation. Appetite changes are usually noticeable within the first week or two.
Weeks 5 to 8: 5 mg weekly. This is the lowest therapeutic dose and produces meaningful weight loss for many patients on its own.
Weeks 9 to 12: 7.5 mg weekly. A bridging dose for patients who tolerated 5 mg well and need additional appetite suppression.
Weeks 13 to 16: 10 mg weekly. A common maintenance dose for patients with substantial weight loss goals.
Weeks 17 to 20: 12.5 mg weekly. A bridging step to the highest dose.
Week 21 onward: 15 mg weekly. The maximum maintenance dose, reserved for patients whose response and tolerance justify it.

Not every patient titrates to 15 mg. Some hold at 5 mg or 10 mg as their long-term maintenance dose because they have reached a satisfactory weight or because side effects do not justify pushing higher. The clinical decision at each step is whether the additional appetite suppression and weight loss are worth the additional side effect risk for that patient.

Common Side Effects and How They Compare to Semaglutide

The side-effect profile of tirzepatide is similar in pattern to semaglutide but somewhat different in intensity. Gastrointestinal effects, especially nausea, are the most common reason patients discontinue either medication. The trial data shows nausea in approximately 24 to 33% of tirzepatide patients depending on the dose, compared to 44% on semaglutide 2.4 mg. The difference is real but modest, and individual patient experience varies considerably.

Other GI symptoms, including diarrhea, constipation, and reflux, occur at rates similar to semaglutide. Most are mild, dose-dependent, and improve over the first few weeks at each dose step. Following the standard titration schedule, eating smaller meals, avoiding high-fat foods, and staying well hydrated all help. Patients who push through the titration steps faster than the schedule recommends typically experience more severe GI symptoms (FDA prescribing information for incretin-based therapies).

The non-GI side-effect profile is similar between the two medications. Hair shedding is reported by a small percentage of patients on either drug, with the same telogen effluvium mechanism tied to rapid weight loss. Muscle loss is a concern with both medications and is addressed with the same protein-and-resistance-training protocol. Hypoglycemia is rare in non-diabetic patients but possible in patients on other glucose-lowering medications.

Tirzepatide carries the same boxed warning as semaglutide regarding medullary thyroid carcinoma based on rodent studies. The clinical relevance in humans remains uncertain, but patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are not candidates for either medication.

Who Is a Good Candidate for Tirzepatide?

The candidacy criteria for tirzepatide overlap heavily with semaglutide. The standard threshold is a BMI of 30 or higher, or a BMI of 27 or higher with weight-related comorbidities. The same contraindications apply. The same lab and history workup is appropriate before starting.

Specific patient profiles that often favor tirzepatide over semaglutide include patients with substantial weight loss goals where the additional 5 to 10 percentage points of expected loss matters; patients with co-existing type 2 diabetes or significant insulin resistance, where the dual-receptor mechanism produces larger improvements in glucose handling; and patients who have plateaued on semaglutide and want to access additional weight loss through a different mechanism. Our broader candidacy guide covers the foundational eligibility criteria that apply to both medications.

Patients who tolerated semaglutide poorly may or may not tolerate tirzepatide better. The mechanism overlap means that a patient with severe nausea on semaglutide is more likely than average to have nausea on tirzepatide too, though the rates are somewhat lower. The decision to switch is a clinical judgment that should weigh tolerance history alongside expected response.

What to Expect at a Tirzepatide Consultation at Body Works

The initial consultation for tirzepatide treatment at Body Works covers the same ground as a semaglutide consultation: comprehensive lab work, a detailed health history, body composition assessment, and a discussion of goals and lifestyle context. The medication choice is made within that broader picture rather than as a default first step.

For patients new to GLP-1 treatment, the conversation about whether to start with semaglutide or tirzepatide considers the weight loss goal, the metabolic profile, the side-effect tolerance history with other medications, and cost considerations. For patients switching from semaglutide, the conversation includes why the switch is being considered, what response was seen on semaglutide, and what dosing transition makes sense.

The titration schedule, follow-up cadence, and the supporting infrastructure for protein, resistance training, and lab monitoring are all built into the plan from the start. Patients leave the initial consultation with a clear protocol, not a vague prescription. Schedule a free consultation to talk through whether tirzepatide is the right starting point for your situation, or whether a different medication or sequence makes more clinical sense.

Frequently Asked Questions

How much weight can I lose on tirzepatide?

The SURMOUNT-1 trial showed an average of 22.5% body weight loss at the 15 mg dose over 72 weeks. For a 220-pound patient, that is approximately 50 pounds. Roughly 40% of patients lost at least 25% of body weight, and around 15% lost at least 30%. Individual results vary substantially depending on starting weight, dose tolerance, and lifestyle support.

Is tirzepatide stronger than semaglutide?

In head-to-head clinical comparisons, tirzepatide produces larger average weight loss than semaglutide at maximum doses, around 22.5% vs 14.9% over comparable trial durations. Tirzepatide also produces larger improvements in glucose handling. Whether stronger is better depends on the patient. Larger weight loss potential means more value for patients with higher weight loss goals; for patients with modest goals, the additional appetite suppression may not be necessary.

How long does it take to see results on tirzepatide?

Appetite changes typically begin within the first week or two of starting the 2.5 mg titration dose. Scale changes accelerate as the dose increases. Most patients lose six to twelve pounds in the first three months, with the rate of loss continuing through months three to twelve. Full therapeutic effect is reached at the maintenance dose, usually somewhere between weeks 12 and 24 depending on individual titration speed.

What is the maximum dose of tirzepatide?

The maximum dose for chronic weight management is 15 mg weekly. Not every patient needs to titrate to 15 mg; many achieve their goals at 5 mg or 10 mg as a long-term maintenance dose. The decision to push higher depends on the patient’s continued response, side-effect tolerance, and how far their current weight is from their goal.

Can I switch from semaglutide to tirzepatide?

Yes, and many patients do. The switch is usually done by stopping semaglutide and starting tirzepatide at the standard 2.5 mg titration dose, rather than attempting a dose-equivalent jump. The rationale for switching is most often a plateau on semaglutide, an inadequate response, or a clinical preference for the dual-receptor mechanism. The decision should involve a provider review, not just a self-directed swap.

Does tirzepatide cause more side effects than semaglutide?

Trial data suggests tirzepatide produces somewhat lower rates of nausea than semaglutide at maximum doses, though both medications have meaningful GI side-effect profiles. Other side effects, including hair shedding, muscle loss risk, and constipation, occur at similar rates. Individual patient experience varies considerably, and tolerance is not predictable from trial averages.

Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN

Browse Our Blog

Loose Skin After Weight Loss: Causes, Prevention, and Treatment

August 10, 2026

Loose skin after major or GLP-1 weight loss is common, and it worries a lot of people. Here is what causes it, which factors decide

Body Changes After GLP-1 Weight Loss: The Complete Guide

August 6, 2026

Rapid weight loss changes more than the number on the scale. Here is what happens to your face, skin, muscle, and body shape on GLP-1

GLP-1s and Hormone Therapy for Women: What New Research Shows

August 2, 2026

A new retrospective study found postmenopausal women on tirzepatide lost noticeably more weight when they also used menopause hormone therapy. Here is what the research

GLP-1 Pill vs Injection: What to Know About Oral GLP-1s

July 29, 2026

Oral GLP-1 medications promise the same appetite control as injections without the needle, but strict fasting windows and absorption limits change the picture. Here is

Skin Tightening After Weight Loss: Non-Surgical Options Compared

July 25, 2026

Loose skin after weight loss has more non-surgical options than ever. Here is how the main skin tightening approaches compare and how to choose one.

Is Ozempic Face Reversible? What Fillers and Collagen Can and Cannot Do

July 22, 2026

Rapid weight loss can leave the face looking hollow. Here is an honest look at what dermal fillers, biostimulators, and collagen support can and cannot

GLP-1 Weight Loss for Women in Menopause and Perimenopause: What Changes and What Helps

Posted on April 24, 2026May 11, 2026 by Dr. Donald Vollmer, MD

GLP-1 Weight Loss for Women in Menopause and Perimenopause: What Changes and What Helps

April 24, 2026

The weight gain that arrives during perimenopause is genuinely different from weight gain at other times of life. It often shows up around the midsection where it was not before. It resists the diet and exercise approaches that worked at thirty-five. It tracks with sleep changes, mood shifts, and a metabolism that seems to have changed the rules without telling anyone. Patients in their forties and fifties describe it as fighting a different opponent, and they are not wrong.

GLP-1 medications have become a useful tool for many women navigating midlife weight gain, but the conversation around them often skips the parts that matter most for this population. Hormonal context shapes how the medication performs. Bone density, muscle mass, and cardiovascular risk all need closer attention in midlife than in earlier decades. Hormone therapy, if a patient is also using it, interacts with weight loss strategy in ways that should be explicit, not assumed.

This guide is for women in perimenopause or menopause considering whether physician-supervised semaglutide therapy or tirzepatide fits into a broader midlife health strategy. It covers the hormonal biology behind the weight pattern, what the evidence shows for GLP-1 effectiveness in this population, the side-effect questions that matter more after forty, and how a combined approach that addresses both hormones and metabolism produces better outcomes than either piece alone.

Why Weight Changes During Perimenopause and Menopause

The weight pattern in midlife reflects a cluster of physiological changes happening at the same time. Estrogen levels begin to fluctuate during perimenopause, which can start as early as the late thirties for some women, and decline more steadily after menopause. Estrogen has direct effects on body composition: it influences where fat is stored, how the body processes carbohydrate, and the sensitivity of insulin signaling.

As estrogen declines, fat storage shifts from the hips and thighs to the abdomen. The midsection accumulation is not a cosmetic difference. Visceral fat, the fat surrounding internal organs, is metabolically active in ways that subcutaneous fat is not. It produces inflammatory signals, contributes to insulin resistance, and elevates cardiovascular risk. The metabolic profile of a midlife woman who has gained twenty pounds in the abdomen is meaningfully different from the metabolic profile of the same woman twenty pounds heavier at thirty.

At the same time, age-related muscle loss, called sarcopenia, accelerates after forty if not actively countered. Less muscle means a lower resting metabolic rate, which means the same eating pattern that maintained weight in the past now produces a slow gain. Sleep disruption from hot flashes and night sweats further dysregulates the appetite hormones leptin and ghrelin, increasing hunger and reducing fullness signals (North American Menopause Society on menopause and weight).

The cumulative effect is that midlife weight gain is multifactorial. Diet and exercise alone often produce smaller results than they did a decade earlier, not because effort is lower but because the physiology is different. This is the context in which GLP-1 medications become a clinically reasonable consideration.

Are GLP-1 Medications Effective for Menopausal Weight Gain?

The major GLP-1 trials for weight management included substantial numbers of women in midlife, though they were not designed as menopause-specific studies. Subgroup analyses and follow-up research consistently show that women in the 45 to 65 age range respond to semaglutide and tirzepatide at rates similar to younger women, with average weight loss in the same 14 to 22 percent range depending on the medication and dose (Jastreboff et al., New England Journal of Medicine, 2022).

The weight loss tends to come disproportionately from visceral abdominal fat, which is the metabolically dangerous compartment. This means GLP-1 treatment in midlife often produces cardiovascular and metabolic benefits that exceed what the scale number alone suggests. Insulin sensitivity improves. Blood pressure often comes down. Lipid panels frequently shift in a favorable direction. For midlife women whose weight gain is intertwined with prediabetes, hypertension, or fatty liver, these secondary effects are sometimes more clinically meaningful than the weight number itself.

The medications are not magic. The weight loss is real, but it requires the same supporting infrastructure that any weight loss requires: adequate protein, resistance training to preserve muscle, sleep prioritization, and consistent follow-up. These elements matter more, not less, in midlife.

The Hormone Therapy Connection

Many women in perimenopause and menopause are candidates for hormone therapy, which addresses estrogen and sometimes progesterone deficiency directly. Hormone therapy, when clinically appropriate, has its own effects on body composition. It modestly reduces abdominal fat accumulation, supports bone density, and improves the metabolic profile in ways that complement, rather than duplicate, what GLP-1 medications do.

Patients pursuing both interventions should be working with providers who understand both. Hormone therapy can change appetite patterns. GLP-1 medications can change how patients perceive hot flashes and other vasomotor symptoms. Lab work overlaps. The clinical conversation about cardiovascular risk, breast health, and venous thromboembolism risk all factor in. Coordinating both treatments under one clinical roof, or under tightly aligned providers, produces a cleaner protocol than running them in parallel through unconnected services.

Body Works provides both medical weight loss with GLP-1 medications and women’s hormone therapy. The clinical adjacency is one of the reasons the program is well suited to midlife patients. The same provider who prescribes the GLP-1 sees the hormone panel, knows the hot flash trajectory, and can build a single coherent plan rather than two parallel protocols.

The strongest evidence for this combined approach came in early 2026. A retrospective cohort study led by Mayo Clinic researchers, published in The Lancet Obstetrics, Gynaecology and Women’s Health, followed 120 postmenopausal women on tirzepatide for at least twelve months. Women who were also on systemic hormone therapy lost an average of 19.2 percent of their starting body weight, compared to 14.0 percent in women on tirzepatide alone (Castaneda et al., The Lancet Obstetrics, Gynaecology and Women’s Health, 2026). The share of women losing more than 20 percent of body weight was 45 percent in the hormone-therapy group, compared to 18 percent without it.

The study cannot prove causation because patients were not randomized. But the magnitude of the difference, and the consistency with the underlying biology, is large enough that midlife patients deserve to have hormone therapy explicitly discussed alongside any GLP-1 decision. The two treatments are not in competition. They appear to amplify each other.

Side Effects to Watch in Midlife Women

Several side-effect considerations apply more strongly in midlife than in younger patients. Bone density is the most important. Rapid weight loss in any population can be associated with reduced bone mineral density, and postmenopausal women already face accelerated bone loss from estrogen decline. The protective strategy is identical to the protective strategy for muscle: adequate protein, vitamin D, calcium, and consistent resistance training. Patients with a personal or family history of osteoporosis warrant a baseline DEXA scan before starting an aggressive weight loss protocol.

Muscle preservation matters more in midlife because the baseline rate of sarcopenia is higher. Preserving muscle on GLP-1 medications in this age group requires deliberate attention to protein intake at the upper end of clinical recommendations and a non-negotiable resistance training component.

Hair changes, which are already common in midlife due to hormonal shifts, may overlap with the temporary telogen effluvium associated with rapid weight loss. The combination can be more visible than either cause alone. Recognizing the dual contribution helps avoid attributing all of it to the medication when hormones are also a factor.

Cardiovascular risk monitoring is also worth attention. Most midlife women on GLP-1 medications see favorable cardiovascular markers over time, but baseline assessment, including a lipid panel, blood pressure tracking, and consideration of HbA1c, gives the provider the data needed to identify a problem early if one emerges.

Who Is and Is Not a Good Candidate in Midlife?

The general candidacy questions for GLP-1 medications apply in midlife, with a few modifications. The standard threshold is a BMI of 30 or higher, or a BMI of 27 or higher with weight-related comorbidities. Comorbidities are more common in midlife, so more women in the 27 to 30 BMI range qualify on the comorbidity criterion than they might have understood.

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are not candidates. Patients with active gallbladder disease, pancreatitis, or severe gastroparesis warrant a careful clinical evaluation before starting. Patients on certain other medications may need dose adjustments or monitoring changes.

The broader fit question, beyond the medical criteria, is whether the patient is positioned to add the supporting work that makes the medication effective. Resistance training, protein focus, sleep prioritization, and stress management are not optional add-ons in midlife. They are part of the protocol. A patient who is able to build those elements into the plan is positioned for excellent outcomes. A patient who is not is better served by addressing those foundations first and revisiting medication later. Our broader candidacy guide for who is a good candidate for semaglutide covers the medical criteria in more depth.

How a Combined Approach Looks at Body Works

Patients in midlife who come to Body Works typically receive a more integrated initial assessment than patients in other age groups. Lab work includes a full thyroid panel, comprehensive metabolic panel, lipid panel, vitamin D, ferritin, and HbA1c. For patients open to it, hormone panels evaluate where they sit in the perimenopause-to-menopause transition. The conversation is explicit about the interaction between hormonal status and weight loss strategy.

Treatment planning then accounts for the full picture. Some patients are best served by GLP-1 treatment alone, with the hormonal symptoms managed separately or not at all. Some are best served by hormone therapy first, with weight management revisited after hormonal status is stable. Some benefit from both approaches launched in coordination, with each treatment adjusted as the patient responds. The goal is a single coherent plan, not two unrelated services.

Resistance training guidance, protein targets, and bone health protocols are built into the plan from the start. Follow-up visits track multiple markers, not just the scale, because the cardiovascular and metabolic improvements often outpace the weight loss in clinical importance for this population. Schedule a free consultation to talk through how a combined plan would look for your specific situation.

Frequently Asked Questions

Does semaglutide work for menopausal weight gain?

Yes. Subgroup analyses of the major GLP-1 trials show women in the 45 to 65 age range respond to semaglutide at rates similar to younger women, with weight loss in the 14 to 17 percent range on average over 68 weeks. Tirzepatide produces somewhat larger losses. The visceral abdominal fat that drives midlife metabolic risk responds particularly well to GLP-1 treatment.

Can I take semaglutide and hormone therapy at the same time?

Yes, and many midlife women do. The two treatments address different aspects of midlife health and are not pharmacologically incompatible. Coordinating both under one provider, or under tightly aligned providers, produces a cleaner clinical picture than managing them through unconnected services. Lab work and follow-up cadence often overlap.

Will semaglutide help with hot flashes?

Semaglutide is not a treatment for hot flashes, and the medications are not designed to address vasomotor symptoms. Some patients report indirect improvement in sleep quality and overall comfort as weight loss progresses, but if hot flashes are the primary concern, hormone therapy is the more appropriate intervention to consider.

Does GLP-1 affect bone density in postmenopausal women?

Rapid weight loss in any population can be associated with reduced bone mineral density, and postmenopausal women already face accelerated bone loss. The protective strategy is the same regardless of medication: adequate protein, vitamin D, calcium, and consistent resistance training. Patients with osteoporosis risk factors warrant a baseline DEXA scan before starting an aggressive weight loss protocol.

What protein intake do I need on a GLP-1 in midlife?

Most clinical guidelines suggest 1.2 to 1.6 grams of protein per kilogram of body weight per day during active weight loss. For midlife women, the upper end of that range is usually the better target because muscle preservation is more difficult after forty. A 160-pound patient at 1.6 g per kg works out to roughly 116 grams of protein per day.

How is medical weight loss in midlife different from in younger women?

The medical and behavioral protocols are similar, but the supporting infrastructure matters more in midlife. Resistance training is non-negotiable rather than recommended. Bone density, cardiovascular markers, and lab work are tracked more closely. The interaction with hormonal status, whether the patient is in perimenopause, menopause, or on hormone therapy, becomes part of the clinical picture rather than a separate concern. A program built for midlife women accounts for these differences explicitly rather than treating midlife as a default case.

Is GLP-1 more effective if I am also on hormone therapy?

Recent evidence suggests yes. A 2026 retrospective study from Mayo Clinic, published in The Lancet Obstetrics, Gynaecology and Women’s Health, found that postmenopausal women on tirzepatide combined with systemic hormone therapy lost an average of 19.2 percent of their body weight over 12 months, compared to 14.0 percent in women on tirzepatide alone. About 45 percent of women on the combination crossed the 20 percent weight loss threshold, versus 18 percent without hormone therapy. The study was retrospective, not randomized, but the magnitude of the difference is meaningful, and the biology is consistent with hormone therapy and GLP-1 medications addressing different parts of the same metabolic problem.

Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN

Browse Our Blog

Loose Skin After Weight Loss: Causes, Prevention, and Treatment

August 10, 2026

Loose skin after major or GLP-1 weight loss is common, and it worries a lot of people. Here is what causes it, which factors decide

Body Changes After GLP-1 Weight Loss: The Complete Guide

August 6, 2026

Rapid weight loss changes more than the number on the scale. Here is what happens to your face, skin, muscle, and body shape on GLP-1

GLP-1s and Hormone Therapy for Women: What New Research Shows

August 2, 2026

A new retrospective study found postmenopausal women on tirzepatide lost noticeably more weight when they also used menopause hormone therapy. Here is what the research

GLP-1 Pill vs Injection: What to Know About Oral GLP-1s

July 29, 2026

Oral GLP-1 medications promise the same appetite control as injections without the needle, but strict fasting windows and absorption limits change the picture. Here is

Skin Tightening After Weight Loss: Non-Surgical Options Compared

July 25, 2026

Loose skin after weight loss has more non-surgical options than ever. Here is how the main skin tightening approaches compare and how to choose one.

Is Ozempic Face Reversible? What Fillers and Collagen Can and Cannot Do

July 22, 2026

Rapid weight loss can leave the face looking hollow. Here is an honest look at what dermal fillers, biostimulators, and collagen support can and cannot

Compounded Semaglutide: What to Look For, What to Avoid, and Why the Source Matters

Posted on April 22, 2026May 11, 2026 by Dr. Donald Vollmer, MD

Compounded Semaglutide: What to Look For, What to Avoid, and Why the Source Matters

April 22, 2026

For most of 2023 and 2024, Body Works semaglutide therapy was on the FDA shortage list. That single regulatory designation opened the door for compounding pharmacies to legally produce semaglutide for patients who could not access the brand-name version. By the time the shortage ended, hundreds of thousands of patients were receiving compounded semaglutide through telehealth platforms, weight loss clinics, and direct-to-consumer pharmacy channels. The supply pattern reshaped the entire weight loss medication market.

The shortage status changed in 2025, and the rules around compounding tightened. Some compounded semaglutide is still legally produced under specific clinical conditions. Some is not. The difference matters because not every vial labeled “compounded semaglutide” is the same product, and the variation between sources includes safety-relevant details that patients usually do not see on the label.

This guide explains what compounded semaglutide actually is, where the safety lines fall, and what to ask any provider, telehealth service, or pharmacy before you take a vial home. The goal is not to argue that compounded semaglutide is universally bad or universally fine. The goal is to give you the questions that separate a careful provider from a careless one, because that distinction is what determines whether the medication you are taking is what you think it is.

What Is Compounded Semaglutide?

Compounded medications are drugs prepared by a licensed pharmacy from raw active pharmaceutical ingredients, rather than dispensed from a manufacturer-finished sealed vial. Compounding is a legitimate, long-established part of pharmacy practice. It exists to handle clinical situations where a manufactured product does not fit a specific patient’s needs, such as a patient who is allergic to a preservative in the manufactured version, a child who needs a smaller dose than the manufactured strength, or a patient whose medication is in legitimate shortage.

The Federal Food, Drug, and Cosmetic Act allows compounding under two distinct categories. Section 503A pharmacies are state-licensed and produce custom preparations for individual patients with valid prescriptions. Section 503B outsourcing facilities are federally registered and can produce larger batches under stricter quality standards, often supplying clinics directly. Both categories were active producers of compounded semaglutide during the shortage.

The active pharmaceutical ingredient itself, semaglutide, is the same molecule whether it comes from a brand-name vial or a compounded preparation. What differs is the supply chain for the raw material, the formulation excipients, the quality of the compounding process, the sterility and potency testing, and the regulatory oversight applied to each lot.

503A Versus 503B: Why the Type of Pharmacy Matters

503A pharmacies are regulated primarily at the state level. They must operate under a valid prescription for an individual patient, and the compounding process is reviewed by state boards of pharmacy. Quality varies, sometimes significantly, depending on the specific pharmacy. Some 503A pharmacies operate to standards that approach 503B levels. Others do not.

503B outsourcing facilities are registered with the FDA, inspected against current Good Manufacturing Practices, and required to meet stricter standards for testing, documentation, and recall procedures. The compromise is that 503B preparations cannot be dispensed for an individual patient on a one-off basis the way 503A preparations can. They are typically supplied in batches to clinics for in-office administration.

For a patient evaluating a compounded semaglutide source, the first practical question is which type of pharmacy supplies it. The second is whether that pharmacy publishes inspection records and test results. A reputable supplier provides this information without resistance. A supplier that cannot or will not is a signal that the patient should look elsewhere (National Association of Boards of Pharmacy).

The Salt-Form Problem

The brand-name versions of semaglutide are formulated as the semaglutide base. Some compounded preparations during the shortage period were produced using semaglutide salt forms, specifically semaglutide sodium and semaglutide acetate. The FDA issued a compounding alert in 2023 noting that these salt forms are not the same active ingredient as approved semaglutide and have not been demonstrated to be safe and effective in humans (FDA Drug Safety Communication on compounded semaglutide).

The salt-form issue matters because two preparations labeled “semaglutide” are not necessarily delivering the same molecule to your bloodstream. A patient who tolerates and responds well to semaglutide base may have a different experience with a salt-form preparation, and the safety data for salt forms in chronic dosing is essentially nonexistent.

A patient considering a compounded source can simply ask: “Is this compounded from semaglutide base, or from a salt form?” A provider who does not know the answer is not in a position to advise you on the safety of the medication they are prescribing. A provider who specifies semaglutide base and can document the source of the active ingredient is operating at a different level.

How the Shortage Resolution Changed Compounding Rules

When semaglutide was on the FDA shortage list, compounding under section 503A was broadly permitted as a way to maintain patient access. The shortage status changed in 2025, and the rules tightened. Compounded semaglutide is still legally produced for patients with documented clinical reasons that the manufactured product does not fit, but the bar for what counts as a valid clinical reason is higher than it was during the shortage.

Some telehealth services that scaled rapidly during the shortage are now operating in a more constrained environment, and the legality of certain mass-market compounded prescriptions is in active dispute. Patients who started compounded semaglutide during the shortage and are still on it should understand that the clinical and regulatory landscape has shifted, and that a careful provider review is appropriate.

This is one of several reasons that choosing between in-person and online GLP-1 care is a more consequential decision than most patients realize. An in-person provider can re-evaluate the source, the dose, and the appropriateness of the medication as the regulatory environment changes. A subscription telehealth platform that ships a vial every month may not perform that re-evaluation at all.

How to Evaluate Whether a Compounded Source Is Safe

Several specific questions reveal a lot about a compounded supplier’s quality. Asking them, and noticing how they are answered, separates the providers worth working with from those worth avoiding.

Is the pharmacy a 503A or 503B facility, and can the inspection records be shared? Both types can produce safe preparations, but the patient deserves to know which they are receiving and to verify the pharmacy’s regulatory standing.

Is the active ingredient semaglutide base, and where is it sourced? Semaglutide base is the form used in the manufactured products and is what the long-term safety data supports. Salt forms are a different molecule and lack that data.

What are the sterility and potency test results for the lot being dispensed? Reputable compounding pharmacies test each lot for sterility, endotoxin, potency, and stability. The results are documentable. A pharmacy that cannot produce them on request is not operating at the standard a patient should accept.

Who reviews adverse events, and what is the process for reporting them? Patients on any compounded medication should have a defined channel for reporting side effects, and the provider should be tracking and aggregating the reports. Subscription services that disclaim responsibility for adverse events at the click-through level are not the right place to take a chronic medication.

The same checklist applies to any prescription a patient receives, but it is especially important for compounded preparations where the regulatory backstop is thinner than for manufactured products. Our guide to spotting weight loss medication scams covers the broader red flags, and most of them apply to evaluating compounded sources as well.

Why Body Works Vets Sourcing Carefully

Body Works does not subscribe to a single sourcing model that fits every patient. The right product, dose, and supply chain depend on the patient’s clinical profile, response history, and the current regulatory context. What is consistent is the diligence applied to whichever source is used. Pharmacy partners are vetted for licensure, inspection history, and willingness to share testing documentation. The active ingredient is verified as semaglutide base when compounded preparations are appropriate. The dose, formulation, and supply are reviewed at each follow-up visit, not assumed to be unchanged from the prior month.

Patients are also informed about what they are being prescribed, why, and what the alternatives are. If a brand-name product is the right fit, that is the recommendation. If a compounded preparation from a vetted 503B facility is the right fit, that is the recommendation, and the reasoning is documented. The point is that the decision is clinical, not commercial.

The patients most at risk from compounded semaglutide are not the ones receiving it through a careful program with documented sourcing. They are the ones receiving it through high-volume subscription channels with minimal oversight, where the product, the active ingredient, and the dose may not match what the label claims. Schedule a free consultation if you are currently on a compounded preparation and want a second opinion on the source and the protocol you are following.

Frequently Asked Questions

Is compounded semaglutide legal in 2026?

Compounded semaglutide is legal under specific clinical circumstances, but the conditions are narrower than during the 2023 to 2024 shortage period. A compounded prescription must usually document a clinical reason that a manufactured product does not fit the patient. Compounding for general convenience or cost preference is increasingly limited, and certain telehealth distribution models are facing regulatory and legal challenges.

Is compounded semaglutide as effective as the brand-name version?

If the active ingredient is genuine semaglutide base from a reputable pharmacy, the molecule is the same and the clinical effect should be comparable. The variability comes from formulation, sterility, potency consistency, and the supply chain. A well-compounded preparation from a vetted source can deliver similar results. A poorly compounded preparation, or one made from a salt form, may not.

What is the difference between semaglutide base and semaglutide salt forms?

Semaglutide base is the active ingredient used in the manufactured products and is what the clinical safety and efficacy data supports. Semaglutide salt forms, including semaglutide sodium and semaglutide acetate, are chemically related but distinct molecules that have not been demonstrated to be safe and effective in humans for chronic weight management. The FDA issued a compounding alert about the salt forms in 2023.

How do I find out if a pharmacy is 503A or 503B?

503B facilities are listed on the FDA’s registered outsourcing facilities directory. State boards of pharmacy publish lists of licensed 503A pharmacies. Reputable compounding pharmacies disclose their classification and inspection history when asked. A supplier that resists the question or cannot answer it definitively is a supplier worth avoiding.

Why is compounded semaglutide cheaper than the brand-name version?

The cost difference reflects several things, including lower raw-material cost for the active ingredient, no manufacturer marketing or research overhead in the price, and in some cases lower regulatory and quality-control costs. Cheaper is not automatically worse, and not all expensive options are better. The relevant question is what testing, oversight, and clinical support come with the price, not the price alone.

What should I do if I am currently taking compounded semaglutide?

If you have been taking compounded semaglutide and have not had a recent clinical review of the source, the active ingredient, and the protocol, that review is worth scheduling. A provider who can verify the supply chain, evaluate your response, and adjust the plan based on the current regulatory landscape will give you a clearer picture than your subscription portal can. The medication itself is not the problem. Inadequate oversight of any chronic medication is.

Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN

Browse Our Blog

Loose Skin After Weight Loss: Causes, Prevention, and Treatment

August 10, 2026

Loose skin after major or GLP-1 weight loss is common, and it worries a lot of people. Here is what causes it, which factors decide

Body Changes After GLP-1 Weight Loss: The Complete Guide

August 6, 2026

Rapid weight loss changes more than the number on the scale. Here is what happens to your face, skin, muscle, and body shape on GLP-1

GLP-1s and Hormone Therapy for Women: What New Research Shows

August 2, 2026

A new retrospective study found postmenopausal women on tirzepatide lost noticeably more weight when they also used menopause hormone therapy. Here is what the research

GLP-1 Pill vs Injection: What to Know About Oral GLP-1s

July 29, 2026

Oral GLP-1 medications promise the same appetite control as injections without the needle, but strict fasting windows and absorption limits change the picture. Here is

Skin Tightening After Weight Loss: Non-Surgical Options Compared

July 25, 2026

Loose skin after weight loss has more non-surgical options than ever. Here is how the main skin tightening approaches compare and how to choose one.

Is Ozempic Face Reversible? What Fillers and Collagen Can and Cannot Do

July 22, 2026

Rapid weight loss can leave the face looking hollow. Here is an honest look at what dermal fillers, biostimulators, and collagen support can and cannot

Semaglutide Results Timeline: Week-by-Week and Month-by-Month

Posted on April 20, 2026May 11, 2026 by Dr. Donald Vollmer, MD

Semaglutide Results Timeline: Week-by-Week and Month-by-Month

April 20, 2026

The most common question patients ask after their first injection is some version of “when will I see results?” That question is reasonable, but the answer is not a single number. semaglutide therapy in Franklin and Nolensville produces a predictable pattern of changes that unfolds over months, with appetite shifts visible in the first week, scale changes accelerating around weeks four to eight, and the largest single drops happening between months three and twelve. Knowing what to expect at each phase prevents two common mistakes: getting discouraged early when the scale moves slowly, and getting impatient mid-treatment when the rate of loss naturally slows.

This is a week-by-week and month-by-month guide to what the clinical evidence shows, what most patients actually experience, and how the dose titration schedule shapes the curve. The numbers come from the STEP 1 trial of semaglutide 2.4 mg, which is the most rigorous long-term data available, with real-world variation noted where it matters.

If you are still deciding whether semaglutide is right for you, the broader question of candidacy may be a better starting point. This guide assumes you already know semaglutide is a clinical fit and you want to understand the trajectory once treatment begins.

How Semaglutide Works

Before walking through the timeline, a quick note on what the medication is doing. Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that signals the brain when you have eaten enough. The result is two complementary effects: meals satisfy you sooner, and the constant background pull toward food, what patients describe as food noise, fades.

Semaglutide also slows gastric emptying. Food sits in the stomach longer, fullness lasts longer, and the gap between meals stretches without effort. The combination is what produces the trajectory described below: appetite shifts come first, scale changes follow, and the largest cumulative loss arrives between months three and twelve.

Week 1 to Week 4: The Starting Dose

The first month is a titration phase, not a weight loss phase. You start at 0.25 mg once weekly. This dose is low enough that side effects are usually mild, but it is not high enough to drive substantial weight loss for most patients. The job of weeks one through four is letting your body acclimate.

What you should notice in the first week or two is a quiet but unmistakable shift in appetite. Meals feel like they finish sooner. Snacks between meals lose their pull. The constant low-volume thinking about food that many patients describe as food noise begins to fade. Mild nausea, especially in the first one to three days after each dose, is common and usually manageable with smaller meals and avoiding high-fat foods.

Scale changes during this phase average two to four pounds for most patients. Some lose more, some lose nothing, and both are within normal range. The 0.25 mg dose is doing its job if you are tolerating it and noticing appetite changes, even if the scale has barely moved.

Weeks 5 to 8: Stepping Up to 0.5 mg

At week five, the dose typically doubles to 0.5 mg weekly. Appetite suppression deepens. The fullness signal after meals lasts longer. Patients often report that they finish dinner without finishing the plate for the first time in years. Cravings for highly processed or sweet foods often diminish further.

Weight loss begins to accelerate during this window. Cumulative loss by week eight is typically four to eight pounds, or roughly two to four percent of starting body weight. Mild side effects, especially the day after injection, are still possible but usually less intense than the initial titration step.

This is also the phase where patients begin to notice non-scale changes. Clothing fit shifts before the scale shows large drops because fat loss tends to come from the midsection first, where most patients carry the highest concentration. Waist circumference is a useful supplemental measurement during this phase.

Weeks 9 to 16: 1 mg and the First Therapeutic Dose

The dose continues to step up at four-week intervals: 1 mg at week nine, then 1.7 mg at week thirteen for most patients. This is the first time the medication is at a clearly therapeutic level for weight loss, and the rate of loss reflects that. Patients typically lose two to four pounds per month during this window, with cumulative loss reaching ten to twenty pounds by week sixteen.

Side effect intensity may bump up briefly with each dose increase and then settle. Nausea, if it occurred earlier, often returns for a few days after each step before the body adjusts. Constipation becomes more common at higher doses and benefits from increased water intake and fiber.

The visible changes during this phase are substantial. Most patients have dropped a clothing size, have visible facial slimming, and start receiving comments from people who have not seen them recently. Energy and sleep often improve. Patients who started semaglutide for a metabolic indication, like prediabetes or borderline hypertension, often see lab markers begin to move.

Weeks 17 to 20: Reaching the 2.4 mg Maintenance Dose

The full therapeutic dose for chronic weight management is 2.4 mg weekly, reached around week seventeen for most patients. This is the dose used in STEP 1, and it is where the largest sustained appetite suppression happens.

By week twenty, cumulative loss for the average patient is in the range of fifteen to twenty-five pounds, roughly eight to ten percent of starting body weight. Some patients reach this milestone faster, some slower, and the variation is normal.

Patients who reach 2.4 mg with manageable side effects are positioned for the longest part of the weight loss curve, which spans the next several months at the maintenance dose. Patients who tolerated the titration but find 2.4 mg uncomfortable can sometimes hold at 1.7 mg as a slower but still effective dose. This is a clinical decision your provider makes based on tolerance and response.

Months 6 to 12: The Steady-State Loss Phase

The second half of the first year is when the largest cumulative weight loss happens for most patients. The dose is stable. The body has adapted to the medication. Lifestyle habits built during titration are paying off. Loss continues at a rate of two to five pounds per month for most patients, though the pace gradually slows as you approach a metabolic floor.

The STEP 1 trial measured outcomes at week 68, roughly sixteen months. By that point, the average semaglutide patient had lost 14.9% of their starting body weight, compared to 2.4% in the placebo group (Wilding et al., New England Journal of Medicine, 2021). For a 220-pound patient, 14.9% works out to roughly 33 pounds. Around one-third of patients lose 20% or more of their starting weight during this window.

This phase is also where the work shifts. Resistance training matters more, because preserving muscle becomes essential as fat loss continues. Protein targets stay high. Sleep, hydration, and stress management become the variables that separate strong responders from average ones (National Institute of Diabetes and Digestive and Kidney Diseases). Body composition tracking, not just scale weight, gives you a clearer picture of what the medication is doing.

Beyond a Year: Approaching the Plateau

By month twelve, most patients are within a few pounds of where they will land on semaglutide alone. The curve flattens. The body’s set-point regulation has caught up with the medication’s appetite suppression, and weekly weight changes become small. This is not a failure of the medication. It is the natural endpoint of a treatment that lowered the body’s defended weight to a new, lower equilibrium.

Patients still have meaningful options at this point. Some continue at 2.4 mg as a long-term maintenance plan. Some work with their provider to switch to tirzepatide, which is mechanistically distinct and sometimes produces additional loss in patients who have plateaued on semaglutide. Some begin a tapering plan toward a lower maintenance dose. The decision depends on the gap between current weight and goal weight, the response so far, and individual tolerance.

What If You Are Not Losing Weight on Schedule?

About fifteen percent of patients are clinical “non-responders” to semaglutide, defined as patients who have lost less than five percent of body weight by week twelve at the therapeutic dose. Non-response is rarely about willpower. It usually reflects genetic and metabolic differences in how an individual processes GLP-1 receptor activation.

For patients whose loss is slower than expected, several adjustments are worth considering with a provider. Switching to tirzepatide sometimes produces a stronger response because it activates both GIP and GLP-1 receptors. Reviewing thyroid function, insulin sensitivity, and cortisol can identify a metabolic obstacle that the medication alone is not addressing. Reviewing actual food intake, often surprising even to careful patients, sometimes uncovers an unintentional caloric ceiling that has not really been a deficit.

A flat scale at month two is not a failure. A flat scale at month four at the therapeutic dose, with appetite reduction and lifestyle in place, is a signal that the protocol needs adjustment. That is a conversation with your provider, not a moment to abandon treatment.

Frequently Asked Questions

How fast does semaglutide start working?

Appetite changes typically begin within the first three to seven days, even at the 0.25 mg starting dose. Scale changes lag behind. Most patients lose two to four pounds in the first month, with the rate accelerating as the dose increases over the next several weeks.

How much weight will I lose on semaglutide in three months?

The average patient loses six to twelve pounds in the first three months, or roughly three to six percent of starting body weight. Patients who tolerate titration well and reach 1 mg by month three are usually toward the upper end of that range. The biggest cumulative loss happens between months three and twelve, not in the first ninety days.

What is a normal weight loss rate on semaglutide?

One to two pounds per week during the active loss phase is a healthy and sustainable rate. Slower rates are clinically fine and often more comfortable. Faster rates increase the risk of side effects like fatigue, hair shedding, and muscle loss, and faster is not necessarily better. The total trajectory matters more than the weekly number.

When does semaglutide stop working?

Semaglutide does not stop working in the sense of losing its effect. It produces a new lower equilibrium weight, and once the body reaches that equilibrium, scale loss naturally stops. For most patients, this happens between months twelve and eighteen at the maintenance dose. The medication continues to suppress appetite indefinitely while it is being taken.

Why am I not losing weight in month two?

Slow scale movement in month two is common because the dose is still being titrated and your body is still adjusting. Real movement often shows up between weeks five and twelve as the dose climbs. If you are at week twelve at 1 mg or higher with no scale change and noticeable appetite reduction, it is worth a check on protein intake, hydration, and lab work rather than assuming non-response.

Will I keep losing weight after one year on semaglutide?

Most patients see the rate of loss slow significantly between months twelve and eighteen and then stabilize. Continued weight loss past eighteen months is uncommon on semaglutide alone. If your goal weight is still below your stabilization weight, options include switching to tirzepatide, intensifying lifestyle interventions, or accepting a maintenance phase at the new lower weight. Schedule a free consultation to talk through where your trajectory is heading and what the next step would be.

Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN

Browse Our Blog

Loose Skin After Weight Loss: Causes, Prevention, and Treatment

August 10, 2026

Loose skin after major or GLP-1 weight loss is common, and it worries a lot of people. Here is what causes it, which factors decide

Body Changes After GLP-1 Weight Loss: The Complete Guide

August 6, 2026

Rapid weight loss changes more than the number on the scale. Here is what happens to your face, skin, muscle, and body shape on GLP-1

GLP-1s and Hormone Therapy for Women: What New Research Shows

August 2, 2026

A new retrospective study found postmenopausal women on tirzepatide lost noticeably more weight when they also used menopause hormone therapy. Here is what the research

GLP-1 Pill vs Injection: What to Know About Oral GLP-1s

July 29, 2026

Oral GLP-1 medications promise the same appetite control as injections without the needle, but strict fasting windows and absorption limits change the picture. Here is

Skin Tightening After Weight Loss: Non-Surgical Options Compared

July 25, 2026

Loose skin after weight loss has more non-surgical options than ever. Here is how the main skin tightening approaches compare and how to choose one.

Is Ozempic Face Reversible? What Fillers and Collagen Can and Cannot Do

July 22, 2026

Rapid weight loss can leave the face looking hollow. Here is an honest look at what dermal fillers, biostimulators, and collagen support can and cannot

GLP-1 Hair Loss: Why It Happens, How to Prevent It, and When It Grows Back

Posted on April 18, 2026May 11, 2026 by Dr. Donald Vollmer, MD

GLP-1 Hair Loss: Why It Happens, How to Prevent It, and When It Grows Back

April 18, 2026

Hair shedding ranks consistently among the top concerns patients raise before starting Body Works semaglutide therapy program or tirzepatide. Search volume on “does semaglutide cause hair loss” has climbed in lockstep with the medications themselves, and dermatology clinics across the country report a steady stream of questions from GLP-1 patients worried that their treatment is damaging their hair.

The honest answer is that hair shedding does happen for some patients on GLP-1 medications, but the cause is rarely the drug itself. The shedding pattern, the timing, and the resolution all match a well-described condition called telogen effluvium, which is triggered by rapid weight loss regardless of how the loss happened. Understanding the mechanism, the timeline, and the strategies that reduce the risk turns this from a frightening side effect into a manageable, often preventable, part of treatment.

This guide walks through what the clinical evidence shows, when shedding typically starts and stops, and what a physician-supervised medical weight loss program can do to reduce the risk for patients who are already worried about their hair before they start.

Why Does Hair Shedding Happen on GLP-1 Medications?

The hair on your head is in one of three phases at any given moment: anagen (growing), catagen (transitioning), or telogen (resting and shedding). On a normal day, about 85 to 90% of your hair is in anagen, and you shed roughly 50 to 100 hairs as old telogen hairs are pushed out by new anagen growth.

Telogen effluvium is what happens when a stressor pushes a much larger share of hair into the telogen phase at the same time. Two to four months after the trigger, those hairs all reach the end of telogen and shed in a synchronized wave. Patients notice clumps in the shower, increased thinning at the part line, and a temporary visible reduction in density. The condition is not permanent. New anagen hairs replace the shed ones over the following six to nine months, and the hair density typically returns to baseline (American Academy of Dermatology).

Rapid weight loss is one of the most common triggers of telogen effluvium, and this is true whether the loss comes from bariatric surgery, very-low-calorie diets, severe illness, or GLP-1 medications. The medication is not directly attacking your hair follicles. The medication is producing rapid loss, and rapid loss is what the follicles are responding to.

How Common Is Hair Loss on Semaglutide and Tirzepatide?

In the STEP 1 trial of semaglutide 2.4 mg, hair loss was reported by 3.0% of participants compared to 1.0% on placebo, a clinically modest but real difference (Wilding et al., New England Journal of Medicine, 2021). Tirzepatide trials report hair shedding at a similar single-digit rate. Real-world rates may be higher than trial rates because patients in clinical practice often lose weight faster than the average trial participant, and faster loss correlates with stronger telogen effluvium signal.

The pattern is more common in women than in men, partly because women are more likely to notice and report the change and partly because diffuse thinning is more visible in longer hairstyles. Patients with a personal or family history of any pattern of hair thinning may also experience telogen effluvium that unmasks an underlying tendency, with regrowth coming back at slightly lower density than before.

Hair shedding rates on GLP-1 medications are lower than the rates seen after bariatric surgery, where 30 to 40% of patients report some hair loss in the first year. The mechanism is the same; the magnitude is smaller because GLP-1 weight loss is typically more gradual.

When Does the Shedding Start and Stop?

Telogen effluvium does not start the day you begin medication. The shedding wave usually appears two to four months after a substantial weight loss has occurred. For most semaglutide patients, this corresponds to month four through month seven of treatment, when titration has reached the therapeutic dose and the steepest part of the weight loss curve is happening.

The shedding lasts six to twelve weeks at its peak intensity. After that, new anagen growth pushes the shedding back to baseline rates. Visible regrowth, often as short fine hairs around the hairline and part, is detectable around six months after the shed begins. Full density recovery takes nine to twelve months from the shed onset.

If shedding has not begun to subside by month nine of treatment, or if it is accompanied by other unusual symptoms like scalp pain, redness, or patchy bald spots rather than diffuse thinning, the cause is likely something other than telogen effluvium and deserves a dermatology referral. Iron deficiency, thyroid dysfunction, autoimmune conditions, and androgenetic alopecia can all coincide with treatment and may need separate workup.

How to Prevent and Reduce GLP-1 Hair Shedding

Several strategies, used together, meaningfully reduce the risk and severity of telogen effluvium during medical weight loss. None of them are exotic, and most are part of a well-built program already.

Adequate protein intake. Hair is largely keratin, a protein. Inadequate protein during a calorie deficit is a known telogen effluvium trigger independent of the medication. Most clinical guidelines recommend at least 1.2 to 1.6 grams of protein per kilogram of body weight per day during active weight loss, and on the higher end of that range for patients with hair shedding concerns. The same protein target also helps preserve muscle mass during GLP-1 treatment, which is the other reason it matters.

Iron and ferritin. Low ferritin is a common contributor to hair shedding in women, especially women of reproductive age. A baseline ferritin check is part of a thorough lab panel, and a ferritin below 50 ng/mL often warrants supplementation regardless of whether the patient is on a GLP-1.

Vitamin D, zinc, and biotin. Deficiencies in any of these can amplify shedding. A standard nutrition panel screens for them. Routine biotin supplementation in patients without a deficiency does not improve hair, despite the marketing claims.

Avoiding overly aggressive titration. Patients who push to higher doses faster than the standard schedule lose weight faster and trigger stronger telogen effluvium. Following the standard four-week titration interval, or extending it to six to eight weeks if tolerated weight loss is already brisk, reduces the magnitude of the shedding wave (FDA prescribing information for semaglutide).

Topical minoxidil, in selected patients. For patients with strong shedding or with an underlying tendency to thinning, low-strength topical minoxidil shortens the recovery time and supports the regrowth phase. This is a clinical decision that should be made with a provider, not a self-treatment.

When to See a Provider About Hair Loss

Diffuse shedding that begins around month four, peaks for six to twelve weeks, and starts to taper is consistent with telogen effluvium and rarely requires intervention beyond the strategies above. Symptoms that fall outside that pattern deserve evaluation.

Bald patches rather than diffuse thinning suggest alopecia areata or another autoimmune cause. Scalp pain, burning, or redness suggests an inflammatory cause. Hair loss that worsens past month nine of treatment, or hair loss accompanied by fatigue, cold intolerance, or weight changes inconsistent with the treatment plan, suggests a thyroid or systemic cause that should be worked up. Hair loss with a clearly receding hairline rather than a diffuse part-line widening suggests androgenetic alopecia, which has its own treatment path.

None of these patterns are caused by the GLP-1 medication. They can occur during treatment by coincidence, and a provider can sort out which is which.

How Body Works Approaches Hair Concerns During Medical Weight Loss

At Body Works, the conversation about hair starts at the initial consultation. Patients with a personal or family history of hair thinning are flagged for closer attention during titration. Lab work routinely includes ferritin, vitamin D, thyroid panel, and zinc, with supplementation guidance built into the plan when any of those run low.

Protein targets are individualized rather than recommended as a generic number, and the program supports patients with practical strategies for hitting them. For patients who experience shedding mid-treatment, a slightly slower titration, focused micronutrient support, and short-term topical interventions are all on the table. The goal is to deliver the weight loss without paying an unnecessary cost in hair.

Patients are also reminded that the shedding is temporary. Hair density returns. Knowing the timeline reduces the anxiety, and the right combination of nutritional support, paced titration, and patience produces both the weight loss and the regrowth on schedule. Schedule a free consultation to talk through how a personalized plan would handle this and other side-effect concerns.

Frequently Asked Questions

Does semaglutide directly damage hair follicles?

No. The mechanism is telogen effluvium, a temporary shift in the hair growth cycle triggered by rapid weight loss, nutritional changes, and metabolic stress. The follicles themselves are not harmed, and hair density returns over the following six to twelve months once the shedding wave passes.

When does GLP-1 hair loss usually start?

Two to four months after a substantial weight loss has occurred, which for most patients on semaglutide or tirzepatide corresponds to roughly month four through month seven of treatment. Shedding peaks for six to twelve weeks and then tapers as new growth replaces the shed hairs.

Will my hair grow back after I lose weight on semaglutide?

For the great majority of patients, yes. Telogen effluvium is reversible. Visible regrowth typically appears within six months of the shedding starting, and full density recovery takes nine to twelve months. Patients who continue to lose weight at a rapid pace may experience successive smaller shedding waves until the rate of loss stabilizes.

What protein intake reduces hair shedding during weight loss?

Most clinical guidelines suggest 1.2 to 1.6 grams of protein per kilogram of body weight per day during active weight loss, and on the higher end of that range for patients concerned about hair. A 150-pound patient targeting the higher end would aim for roughly 110 grams of protein per day. The same target also protects muscle mass.

Should I take biotin supplements while on a GLP-1?

Routine biotin supplementation in patients without a documented deficiency does not improve hair growth, despite the marketing. High-dose biotin can also interfere with several common lab tests including thyroid panels and troponin. Iron, vitamin D, zinc, and protein are higher-yield targets for hair support.

Can I prevent hair loss by losing weight more slowly?

A more gradual rate of loss does reduce the severity of telogen effluvium. Slowing the titration schedule, holding the dose at a lower step for an extra few weeks, or accepting a moderate rather than aggressive loss rate are all reasonable strategies, particularly for patients with a strong personal or family history of hair thinning. The tradeoff is that the active phase takes longer to reach the goal weight.

Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN

Browse Our Blog

Loose Skin After Weight Loss: Causes, Prevention, and Treatment

August 10, 2026

Loose skin after major or GLP-1 weight loss is common, and it worries a lot of people. Here is what causes it, which factors decide

Body Changes After GLP-1 Weight Loss: The Complete Guide

August 6, 2026

Rapid weight loss changes more than the number on the scale. Here is what happens to your face, skin, muscle, and body shape on GLP-1

GLP-1s and Hormone Therapy for Women: What New Research Shows

August 2, 2026

A new retrospective study found postmenopausal women on tirzepatide lost noticeably more weight when they also used menopause hormone therapy. Here is what the research

GLP-1 Pill vs Injection: What to Know About Oral GLP-1s

July 29, 2026

Oral GLP-1 medications promise the same appetite control as injections without the needle, but strict fasting windows and absorption limits change the picture. Here is

Skin Tightening After Weight Loss: Non-Surgical Options Compared

July 25, 2026

Loose skin after weight loss has more non-surgical options than ever. Here is how the main skin tightening approaches compare and how to choose one.

Is Ozempic Face Reversible? What Fillers and Collagen Can and Cannot Do

July 22, 2026

Rapid weight loss can leave the face looking hollow. Here is an honest look at what dermal fillers, biostimulators, and collagen support can and cannot

What Happens When You Stop Semaglutide or Tirzepatide: Rebound and Maintenance

Posted on April 16, 2026May 11, 2026 by Dr. Donald Vollmer, MD

What Happens When You Stop Semaglutide or Tirzepatide: Rebound and Maintenance

April 16, 2026

Most patients on semaglutide therapy or tirzepatide eventually ask the same two questions: how long do I need to take this, and what happens if I stop? Those questions feel different, but they are really the same conversation viewed from two angles. The answer matters because the choices you make about discontinuing or maintaining your medication shape whether your hard-won progress lasts or disappears.

Here is what the clinical research shows. Stopping a GLP-1 medication abruptly, without any maintenance plan, leads to substantial weight regain in most patients. This is not a willpower problem. It is biology. The same hormones the medication suppresses come back online when the medication leaves your system, and your appetite and fullness signals reset to where they started.

That is not the end of the story. Patients who plan their transition carefully, often with a tapered dose or a structured maintenance phase, can preserve a meaningful share of their weight loss long term. The strategy starts long before you reach your goal weight. It is built into a physician-supervised program from the beginning, and it is the difference between viewing medical weight loss as a sprint and viewing it as a long-term health intervention.

What Happens to Your Weight When You Stop Semaglutide?

The most rigorous data on semaglutide discontinuation comes from a follow-up to the STEP 1 trial. Patients who lost an average of 17.3% of their body weight over 68 weeks on semaglutide 2.4 mg were taken off the medication and followed for one additional year. By week 120, they had regained roughly two-thirds of the weight they originally lost (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

This regain pattern was not caused by patients abandoning their lifestyle changes. The trial included continued behavioral counseling. The weight came back primarily because the medication was no longer suppressing appetite, slowing gastric emptying, or amplifying satiety signals. When the drug effect ended, the underlying biology of obesity returned.

The takeaway is not that semaglutide does not work. It plainly does. The takeaway is that the medication treats a chronic condition, and most patients need a long-term strategy that does not assume a clean exit at the end of an active loss phase.

Why Does Weight Come Back? The Biology of Rebound

GLP-1 medications work through several mechanisms simultaneously. They activate GLP-1 receptors in the brain and gut, reducing hunger signals and increasing the sense of fullness after meals. They slow the rate at which food leaves the stomach, which extends satiety. They also improve insulin sensitivity and dampen the reward response to high-calorie food.

When the medication is discontinued, all four of those effects reverse on a similar timeline. Ghrelin, the hormone that drives appetite, climbs back to baseline within weeks. Gastric emptying returns to normal speed. The food-reward circuits in the brain stop being suppressed. Patients describe this as the return of food noise, an experience that becomes especially noticeable after months of relative quiet on medication.

Body weight regulation is also defended by what researchers call metabolic adaptation. After significant weight loss, the body lowers its resting metabolic rate and increases hunger signaling in an attempt to restore lost mass. This effect is documented across all weight loss interventions and is one of the reasons sustained loss is harder than initial loss (National Institute of Diabetes and Digestive and Kidney Diseases).

How Tirzepatide Discontinuation Compares to Semaglutide

Tirzepatide produces larger initial weight loss than semaglutide in head-to-head clinical comparisons, but the discontinuation pattern is very similar. The SURMOUNT-4 trial randomized patients who had lost weight on tirzepatide to either continue the medication or switch to placebo. The continued group preserved their weight loss. The placebo group regained about 14% of body weight over the next year, while the continuation group lost an additional 5.5% (Aronne et al., JAMA, 2024).

The pattern is consistent across both medications: continued treatment preserves weight loss, abrupt discontinuation reverses much of it. Tirzepatide may produce a slightly slower regain trajectory than semaglutide because of its dual GIP and GLP-1 mechanism, but both drugs require a thoughtful exit plan.

For patients weighing the choice between the two medications, the regain risk is similar enough that it should not drive the decision. Choosing between semaglutide and tirzepatide turns on tolerance, response, and your provider’s clinical judgment, not on which one is easier to stop.

The Maintenance Question: How Long Should You Stay on a GLP-1?

Major medical organizations now classify obesity as a chronic disease that often requires long-term treatment, similar in framing to hypertension or type 2 diabetes. The American Medical Association formally adopted this classification in 2013, and the American Heart Association reaffirmed it in 2021. From this perspective, expecting a fixed treatment duration for obesity is like expecting a fixed treatment duration for high blood pressure. Some patients can taper or discontinue successfully. Many cannot, and that is a clinical reality, not a failure of effort.

In practice, patients fall into a few patterns. Some stay on a maintenance dose indefinitely. Some taper to a lower dose and stay there. Some complete an active loss phase, transition off the medication entirely, and rely on intensified lifestyle support to hold their weight. The right path depends on your starting weight, your goal weight, your metabolic profile, your response during the active phase, and your tolerance for the medication.

What rarely works is choosing a duration in advance based on a target weight alone. Patients who set themselves a hard stop at month 6 or month 12 and then discontinue without a maintenance plan see the regain pattern described above. Setting the duration question aside until later in treatment, and revisiting it with your provider as data accumulates, leads to better outcomes.

Tapering Versus Stopping Cold Turkey

Tapering means gradually reducing the dose over weeks or months, often to a lower maintenance dose, rather than stopping at the therapeutic dose abruptly. Cold-turkey discontinuation is the pattern that produces the regain numbers from STEP 1 and SURMOUNT-4.

A typical tapering protocol might step a patient down from 2.4 mg semaglutide to 1.7 mg, then 1 mg, then 0.5 mg over three to six months, observing weight stability at each step. Some patients hold at 0.5 mg as a long-term maintenance dose. Others continue down and eventually discontinue, with the lifestyle scaffolding strong enough to hold the weight.

The clinical judgment about when and how to taper involves more than the scale. Body composition, lab work, hunger and satiety self-reports, and lifestyle adherence all factor in. This is where physician supervision earns its keep. A retail subscription model that ships the same dose every month does not have the structure to support a thoughtful taper.

What a Physician-Supervised Maintenance Plan Looks Like

At Body Works, the maintenance question is part of the conversation from your first consultation, not something raised at the end. The active loss phase, typically four to six months, sets the framework for what comes next. Lab work establishes a baseline and tracks metabolic markers. Body composition measurements separate fat loss from muscle loss, which matters because preserving muscle on GLP-1 medications is one of the strongest predictors of weight stability after the active phase.

As patients approach a target weight, the plan transitions. Visits often shift from monthly to every six to eight weeks. Doses are reviewed and adjusted. Nutritional guidance moves from caloric deficit to maintenance, and resistance training becomes more central. For some patients, the maintenance phase is permanent. For others, it is a stepping stone toward eventual discontinuation. Either path is legitimate, and the path that fits you is the one your data and your provider agree on.

The decision points and red flags worth tracking are listed in our guide to what to ask before signing up for medical weight loss. If a clinic does not discuss what happens after you reach your goal during the initial consultation, that is itself a signal about how the program is built.

Signs You May Be Ready to Reduce or Discontinue

There is no single test that says you are ready to taper. A combination of factors usually points in the right direction. Stable weight for at least three months at the maintenance dose. Lab markers that have moved into healthy ranges and stayed there. Established habits around protein intake, resistance training, sleep, and stress management. A realistic understanding that taper attempts sometimes fail and that returning to a maintenance dose is not a setback.

Patients who try to taper without those foundations typically regain. Patients who try to taper with those foundations sometimes still regain, and that is also useful information. A failed taper attempt is not a failure of the patient. It is data that says the body is still defending a higher set point and that ongoing medication is likely the right long-term strategy for that individual.

Frequently Asked Questions

How long do most people stay on semaglutide for weight loss?

There is no single right answer. Some patients stay on semaglutide for 12 to 18 months and then taper. Others stay indefinitely on a maintenance dose. The data suggests that most patients who stop entirely without a structured plan regain a significant share of their weight, so duration decisions should be made with a provider based on your individual metabolic response, not on a target month set in advance.

Will I gain all the weight back if I stop tirzepatide or semaglutide?

Most patients regain a meaningful share of lost weight after stopping abruptly, but rarely all of it. The STEP 1 extension trial showed roughly two-thirds of original weight loss returned by one year off semaglutide. Tirzepatide shows a similar pattern in SURMOUNT-4. A structured taper, continued resistance training, and a maintenance-focused nutrition plan can preserve a larger share of the loss, though preserving all of it without medication is difficult for most patients.

What is the difference between tapering and stopping cold turkey?

Tapering means stepping the dose down over weeks or months, often to a lower maintenance dose, with weight monitored at each step. Cold-turkey discontinuation means stopping at the full therapeutic dose. Cold-turkey discontinuation is the pattern most studied in trials, and it is the pattern that produces the largest regain. Tapering is the standard physician-led approach because it gives the body time to adjust and gives the provider information at each step.

Can I cycle on and off semaglutide?

Cycling, where patients deliberately stop and restart, is not a clinically endorsed protocol. Each restart involves dose titration and the side effects that come with it, and the on-off pattern produces weight fluctuations that may be metabolically harmful. A continuous maintenance dose, even a low one, is generally safer and more effective than repeated cycles.

What happens to muscle mass when I stop a GLP-1 medication?

Muscle change after stopping depends mostly on what you do during and after the medication. Patients who maintained adequate protein intake and resistance training during the active phase are better positioned to hold lean mass through a transition. Patients who did not are at higher risk of regaining weight as fat rather than rebuilding muscle. This is one of the reasons body composition tracking, not just scale weight, matters during a maintenance phase.

Are there ways to keep long-term use affordable?

Several pathways exist depending on the medication and the dose. Manufacturer self-pay programs, lower maintenance doses, and certain compounded options can reduce monthly cost. The right approach is individualized and is part of the maintenance conversation a physician-supervised program should be having with you well before the active loss phase ends. Schedule a free consultation to discuss what a long-term plan would look like for your situation.

Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN

Browse Our Blog

Loose Skin After Weight Loss: Causes, Prevention, and Treatment

August 10, 2026

Loose skin after major or GLP-1 weight loss is common, and it worries a lot of people. Here is what causes it, which factors decide

Body Changes After GLP-1 Weight Loss: The Complete Guide

August 6, 2026

Rapid weight loss changes more than the number on the scale. Here is what happens to your face, skin, muscle, and body shape on GLP-1

GLP-1s and Hormone Therapy for Women: What New Research Shows

August 2, 2026

A new retrospective study found postmenopausal women on tirzepatide lost noticeably more weight when they also used menopause hormone therapy. Here is what the research

GLP-1 Pill vs Injection: What to Know About Oral GLP-1s

July 29, 2026

Oral GLP-1 medications promise the same appetite control as injections without the needle, but strict fasting windows and absorption limits change the picture. Here is

Skin Tightening After Weight Loss: Non-Surgical Options Compared

July 25, 2026

Loose skin after weight loss has more non-surgical options than ever. Here is how the main skin tightening approaches compare and how to choose one.

Is Ozempic Face Reversible? What Fillers and Collagen Can and Cannot Do

July 22, 2026

Rapid weight loss can leave the face looking hollow. Here is an honest look at what dermal fillers, biostimulators, and collagen support can and cannot

Who Is a Good Candidate for Semaglutide? A Complete Guide

Posted on April 13, 2026May 11, 2026 by Dr. Donald Vollmer, MD

Who Is a Good Candidate for Semaglutide? A Complete Guide

April 13, 2026

semaglutide therapy at Body Works weight loss treatment at a medical consultation” />

If you have been struggling to lose weight despite trying diet after diet, you are not alone. For many people in Franklin, TN, Nolensville, TN, and across Middle Tennessee, traditional weight loss methods simply do not deliver the results they need. The CDC Adult Obesity Facts estimate that roughly 40% of U.S. adults meet clinical criteria for obesity, which helps explain why semaglutide has emerged as a powerful option for those who qualify, helping patients achieve significant, sustainable weight loss when other approaches have fallen short.

But semaglutide is not right for everyone. Understanding whether you are a good candidate requires looking at several factors beyond just the number on the scale. At Body Works, we believe in personalized care that considers your complete health picture, not just a single metric. Here is what the FDA guidelines, clinical research, and real-world practice say about who benefits most from semaglutide treatment.

How Does Semaglutide Work for Weight Loss?

Semaglutide belongs to a class of medications called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces to regulate blood sugar and appetite. Semaglutide mimics this hormone, helping you feel fuller faster and stay satisfied longer after meals. It acts on receptors in the brain that control hunger, slows gastric emptying so food stays in your stomach longer, improves insulin response, and reduces the constant mental chatter about food that many patients describe as food noise.

The clinical results are significant. In the landmark STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), half of participants taking semaglutide 2.4 mg lost 15% of their body weight over 68 weeks, and nearly one-third lost 20% or more. Participants making lifestyle changes alone lost only 2.4%. Semaglutide works best when combined with healthy eating habits and regular physical activity: the medication controls appetite, but lasting success comes from building sustainable lifestyle changes alongside treatment. If you want the full mechanism, see our primer on how GLP-1 medications work.

What BMI Qualifies You for Semaglutide?

The FDA approved semaglutide 2.4 mg for chronic weight management in adults who meet one of two criteria: a BMI of 30 or higher (classified as obesity) or a BMI of 27 to 29.9 with at least one weight-related health condition. Your Body Mass Index is calculated from your height and weight, and it serves as the primary starting point for determining candidacy.

To put this in perspective, for someone who is 5’6″ tall, a BMI of 30 equals approximately 186 pounds. A BMI of 27 for the same height equals approximately 167 pounds. A 5’10” adult weighing 195 pounds has a BMI of 28, which qualifies if they also have a weight-related condition. At Body Works, we view BMI as a helpful screening tool, not the final word on your candidacy. Some people with higher muscle mass may have an elevated BMI without excess body fat. Others may have a “normal” BMI but still struggle with metabolic health issues related to weight. That is why we conduct comprehensive evaluations that look beyond this single number.

Weight-Related Conditions That Make You Eligible

If your BMI falls between 27 and 29.9, having certain health conditions may still make you eligible for semaglutide. These conditions, known as comorbidities, are health problems that can be caused or worsened by excess weight. Common qualifying comorbidities include:

Type 2 diabetes: Semaglutide was originally developed to help manage blood sugar, so it offers dual benefits for patients with diabetes
High blood pressure: Excess weight often contributes to elevated blood pressure, which increases heart disease and stroke risk
High cholesterol (dyslipidemia): Abnormal cholesterol levels frequently accompany obesity
Heart disease: Cardiovascular conditions often improve with weight loss
Obstructive sleep apnea: This breathing disorder during sleep commonly resolves or improves with significant weight reduction
Non-alcoholic fatty liver disease (NAFLD): Fat accumulation in the liver affects many people with obesity
PCOS (polycystic ovary syndrome): Women with this hormonal condition often struggle with weight management

The connection between these conditions and weight creates a cycle that is difficult to break through lifestyle changes alone. Semaglutide interrupts the cycle by enabling meaningful weight loss, which often leads to improvement in the related health issues themselves.

Who Should Not Take Semaglutide?

While many people qualify for semaglutide, certain medical conditions make this medication unsafe. During your consultation at Body Works, your provider reviews your complete medical history to ensure semaglutide is appropriate for you. You should not take semaglutide if you have any of the following:

Personal or family history of medullary thyroid carcinoma (MTC): This rare thyroid cancer has been observed in animal studies with GLP-1 medications
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): This inherited condition causes tumors in hormone-producing glands
History of pancreatitis: Previous inflammation of the pancreas increases risk with this medication
Gallbladder disease: Semaglutide may increase the risk of gallbladder problems
Gastroparesis: This condition causes delayed stomach emptying, which semaglutide can worsen
Pregnancy or breastfeeding: Effects on unborn babies and infants are not fully understood
Type 1 diabetes: Semaglutide is not indicated for this condition
Allergies to semaglutide ingredients: Any known hypersensitivity to the medication or its components

Be sure to tell your provider about all medications and supplements you take. Semaglutide can interact with certain antibiotics, retinoids, cortisone products, and other drugs. Full disclosure helps us ensure your safety throughout treatment.

The Body Works Candidate Evaluation Process

Determining whether semaglutide is right for you requires more than checking boxes on a form. The National Institute of Diabetes and Digestive and Kidney Diseases stresses that weight management medications should be prescribed only after a comprehensive medical evaluation that rules out contraindications and identifies the patient most likely to benefit. Body Works Nurse Practitioners and Registered Nurses conduct thorough evaluations that consider your unique health situation, lifestyle, and goals. Here is what to expect during your consultation at either the Franklin or Nolensville location.

Step 1: Comprehensive medical history review. We discuss your weight loss journey, previous attempts, medical conditions, family history, and current medications. This conversation helps us identify any potential contraindications.

Step 2: Physical examination and vital signs. Your provider checks your blood pressure, heart rate, and other vitals, and looks for any physical signs that might affect your treatment plan.

Step 3: Body composition analysis. Beyond BMI, we assess your body composition to understand your muscle mass, body fat percentage, and metabolic health markers.

Step 4: Laboratory testing. Blood work evaluates your blood sugar, cholesterol, liver function, kidney function, and thyroid health. These results ensure semaglutide is safe for you and help track your progress.

Step 5: Discussion of goals and lifestyle. We want to understand your weight loss goals, eating habits, activity level, and any challenges you have faced. This helps us create a realistic, personalized plan.

Step 6: Personalized treatment recommendation. Based on all this information, your provider recommends whether semaglutide is appropriate or if another approach might serve you better. Our approach is judgment-free and supportive, and we have helped hundreds of Middle Tennessee residents achieve lasting weight loss.

What If You Are Not a Candidate for Semaglutide?

If the evaluation determines that semaglutide is not the right choice for you, that does not end the conversation. Body Works offers multiple pathways to help you reach your health and weight loss goals, and sometimes the right answer is a different medication or a different approach entirely.

Alternatives include tirzepatide (a dual GLP-1/GIP receptor agonist that may be appropriate if semaglutide is contraindicated), other FDA-approved appetite suppressants, nutritional counseling with personalized meal planning, IV therapy for metabolism support, and hormone optimization if testing reveals imbalances affecting your weight. Sometimes health conditions change, and a person who does not qualify today may become a candidate in the future. We maintain ongoing relationships with our patients and can re-evaluate your eligibility as your health evolves. Schedule a Free Consultation at either the Franklin or Nolensville location to start the conversation and find out which path fits your situation.

Frequently Asked Questions

How do you know if you are a good candidate for semaglutide?

The simplest answer is that you need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition, and no contraindications like a personal or family history of medullary thyroid cancer, pancreatitis, or pregnancy. A full medical evaluation by a licensed provider is the only way to confirm candidacy. At Body Works, the initial consultation is free and includes a comprehensive assessment.

What qualifies you to get semaglutide?

FDA criteria require a BMI of 30 or greater, or a BMI of 27 to 29.9 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, high cholesterol, heart disease, obstructive sleep apnea, NAFLD, or PCOS. Your provider also reviews your medical history and current medications to confirm there are no safety concerns before prescribing.

Who is not a candidate for semaglutide?

People with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pancreatitis, severe gallbladder disease, gastroparesis, type 1 diabetes, or known allergies to semaglutide should not take this medication. Pregnancy and breastfeeding are also contraindications. Your provider reviews all these factors during the initial evaluation.

Am I a candidate for semaglutide if my BMI is 26?

Under current FDA guidance, a BMI of 26 does not meet the threshold for semaglutide weight loss treatment on its own. The minimum is 27 with a weight-related health condition, or 30 without one. Your provider may discuss alternative approaches such as nutritional counseling, lifestyle coaching, or other treatments that might be more appropriate for your situation.

Can you use semaglutide if you are not overweight?

Semaglutide is not FDA-approved for weight loss in people who are not overweight or obese. Using it outside the approved indications is considered off-label and is not something a responsible medical provider recommends. If you are at a healthy weight but have other concerns about appetite, metabolism, or body composition, your provider can discuss alternative approaches during your consultation.

How quickly can I start semaglutide once I qualify?

In most cases, candidacy is determined during your initial consultation. If lab work is needed, results are typically available within a few days. Once your provider confirms eligibility and reviews the results, you can begin treatment shortly after. Body Works also schedules follow-up visits to monitor your response and adjust dosing as needed during the first months of treatment. Schedule a Free Consultation at Body Works in Franklin or Nolensville to find out if you are a candidate for semaglutide. Medically reviewed by Dr. Donald Vollmer, MD, Managing Physician, Body Works TN

Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN